《大行報告》花旗對輝瑞(PFE.US)開啟90日上行催化觀察
花旗發表報告指,輝瑞(PFE.US)明年指引看似相當保守,該行對公司明年預測較其非通用會計準則( non-GAAP)每股盈測指引範圍高端還高出11%。該行指,留意到公司仍無法解釋將明年撇除新冠、癌症製藥商Seagen(SGEN.US)及其他收益等後收入指引隱含下調20億美元的原因。該行料,隨著治療膀胱癌藥品Padcev獲美國食品藥品管理局(FDA)批准,該藥品將會快速增長。
該行指,雖然明年可見催化劑有限,但繼續視治療惡病質及嘔吐藥物ponsegromab為潛在賺取數以十億計美元的機會,若輝瑞在第二期試驗的基礎上進入第三期試驗,並料將明年得出第二期試驗結果。
該行指,對輝瑞(PFE.US)開啟90日上行催化觀察,給予其目標價為28美元,維持其評級為「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.